Bidil data to be presented at American Heart Association Scientific Sessions.

(From Chemical Business NewsBase - Press Release)

NitroMed Inc will present several oral abstracts that feature post-approval analyses of Bidil (isosorbide dinitrate/hydralazine hydrochloride) data from the company's landmark African American Heart Failure Trial (A-HeFT), at the American Heart Association's Scientific Sessions 2005, being held from 13-16 Nov 2005 in Dallas. Bidil was approved in Jun 2005 US Food and Drug Administration for the treatment of heart failure as an adjunct to current standard therapy in self-identified black patients. The BiDil data to be presented further substantiate A-HeFT trial results, which demonstrated that the patients taking BiDil …